AR010740A1 - Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestos - Google Patents
Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestosInfo
- Publication number
- AR010740A1 AR010740A1 ARP970105506A ARP970105506A AR010740A1 AR 010740 A1 AR010740 A1 AR 010740A1 AR P970105506 A ARP970105506 A AR P970105506A AR P970105506 A ARP970105506 A AR P970105506A AR 010740 A1 AR010740 A1 AR 010740A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- formula
- phenyl
- group
- integer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos de formula (I) y las sales farmacéuticamente aceptables del mismo, donde Z es un grupo de formula (Ia), (Ib), (Ic), (Id), (Ie), (If) en lacuales n es un numero entero de 0 a 2 y p es un numero entero de 0 a 3; R1 es H, alquilo C1-C6o -C(O)(alquilo C1-C6); R2 es fenilo o 1H-indazol-5-ilo,estando dichos grupos opcionalmente sustituidos con 1 a 3 sustituyentes R5 o R2 es un grupo de formula (Ii) o (Ij), en las cuales p es un numero enterode 0 a 3, y n es un numero entero de 0 a 2; o R1 y R2 se unen para formar un grupo de formula (Ik),en las cuales la línea punteada indica unenlace unico o doble, y m es un numero entero de 0 a 4; con la condicion de que cuando Z es un grupo de formula (Ie) y R2 es fenilo, entoncesdicho feniloestá sustituido con 1 a 3 sustituyentes independientemente seleccionados entre alquilo C1-C6, alquinilo C2-C6 y halogeno, y uno de R6 y R7 es halogeno o H, yel otro es como se ha definido anteriormente; y con la condicion adicionalde que cuando Z es un grupo de formula (Ia), (Ib), (Ic) o (Id) y R2 es fenilo,entonces dicho fenilo está sustituido con alquinilo C2-C6. Las composiciones farmacéuticas que contienen los compuestos de formula (I) y losprocedimientos para usar dichos compuestos en el tratamiento de enfermedades proliferativas como el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3186296P | 1996-11-27 | 1996-11-27 | |
US4184697P | 1997-04-09 | 1997-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR010740A1 true AR010740A1 (es) | 2000-07-12 |
Family
ID=26707706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970105506A AR010740A1 (es) | 1996-11-27 | 1997-11-25 | Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestos |
Country Status (24)
Country | Link |
---|---|
US (1) | US6413971B1 (es) |
EP (1) | EP0946554A1 (es) |
JP (1) | JP2000505109A (es) |
KR (1) | KR20000057228A (es) |
CN (1) | CN1237177A (es) |
AP (1) | AP9701146A0 (es) |
AR (1) | AR010740A1 (es) |
AU (1) | AU4718997A (es) |
BG (1) | BG103417A (es) |
BR (1) | BR9713552A (es) |
CA (1) | CA2272705C (es) |
CO (1) | CO4650037A1 (es) |
HN (1) | HN1997000146A (es) |
HR (1) | HRP970641A2 (es) |
ID (1) | ID18958A (es) |
IL (1) | IL129825A0 (es) |
IS (1) | IS5041A (es) |
MA (1) | MA26452A1 (es) |
NO (1) | NO992524D0 (es) |
OA (1) | OA11051A (es) |
PA (1) | PA8442001A1 (es) |
PE (1) | PE17299A1 (es) |
TN (1) | TNSN97192A1 (es) |
WO (1) | WO1998023613A1 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT888349E (pt) * | 1996-01-23 | 2002-10-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
SI0880508T1 (en) | 1996-02-13 | 2003-10-31 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DE69733825T2 (de) | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
CZ20004727A3 (cs) | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
DE60017179T2 (de) | 1999-10-19 | 2006-01-05 | Merck & Co., Inc. | Tyrosin kinaseinhibitoren |
US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
ATE330954T1 (de) | 1999-11-05 | 2006-07-15 | Astrazeneca Ab | Quinazolin-derivate als vegf-hemmer |
AP1905A (en) | 1999-12-10 | 2008-10-20 | Pfizer Prod Inc | Pyrrolo[2,3-d] Pyrimidine Compounds. |
JP2003518123A (ja) | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | 4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
WO2001094353A1 (en) | 2000-06-06 | 2001-12-13 | Pfizer Products Inc. | Thiophene derivatives useful as anticancer agents |
UA74370C2 (uk) | 2000-06-26 | 2005-12-15 | Пфайзер Продактс Інк. | Піроло(2,3-d)піримідинові сполуки як імуносупресори |
WO2002032861A2 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
CA2426654C (en) | 2000-10-23 | 2010-12-21 | Smithkline Beecham Corporation | 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
AU2002361577A1 (en) | 2001-10-30 | 2003-05-12 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
PL371587A1 (en) * | 2002-01-17 | 2005-06-27 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
BR0308162A (pt) | 2002-03-01 | 2004-12-07 | Pfizer | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
NZ539901A (en) | 2002-11-26 | 2007-09-28 | Pfizer Prod Inc | Method of treatment of transplant rejection |
AU2003300898A1 (en) * | 2002-12-13 | 2004-07-09 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
EP1660504B1 (en) | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
CA2537883A1 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | Substituted bicyclic quinazolin-4-ylamine derivatives |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
JP4842929B2 (ja) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | 癌治療に有用なピロロピリミジン誘導体 |
MEP8409A (en) * | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound | |
ZA200610669B (en) * | 2004-06-02 | 2008-06-25 | Takeda Pharmaceutical | Fused heterocyclic compound |
CN101001629B (zh) | 2004-09-17 | 2010-05-05 | 卫材R&D管理有限公司 | 药物组合物 |
GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
DE602006015861D1 (de) | 2005-12-21 | 2010-09-09 | Abbott Lab | Antivirale verbindungen |
EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
JP2009521479A (ja) | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
TWI392677B (zh) * | 2005-12-21 | 2013-04-11 | Abbott Lab | 抗病毒化合物、其製備方法及用途 |
ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
KR20090090336A (ko) | 2006-12-12 | 2009-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합된 헤테로시클릭 화합물 |
WO2008133753A2 (en) * | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
CN104327084B (zh) * | 2007-11-28 | 2017-06-06 | 达那-法伯癌症研究所 | Bcr‑abl的小分子豆蔻酸酯抑制剂及其使用方法 |
JPWO2009113560A1 (ja) | 2008-03-12 | 2011-07-21 | 武田薬品工業株式会社 | 縮合複素環化合物 |
SI2384326T1 (sl) | 2008-08-20 | 2014-06-30 | Zoetis Llc | Pirolo(2,3-d)pirimidinske spojine |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
RU2560683C2 (ru) | 2010-06-25 | 2015-08-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации |
US9139590B2 (en) | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
EP2852595B1 (en) | 2012-05-21 | 2016-06-22 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
US20150218173A1 (en) | 2012-09-26 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
US20150252047A1 (en) | 2012-09-26 | 2015-09-10 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
WO2014085528A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン |
MA40552A (fr) | 2014-08-04 | 2021-05-19 | Nuevolution As | Derives de pyrimidine eventuellement condensee substituee par un heterocycle utiles dans le traitement de maladies inflammatoires, metaboliques, oncologiques et auto-immunes |
EP4089076A1 (en) | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
KR102068423B1 (ko) | 2015-06-04 | 2020-01-20 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
GB201520499D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
MD3497103T2 (ro) | 2016-08-15 | 2021-08-31 | Pfizer | Inhibitori de piridopirimidinonă CDK2/4/6 |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
PL176526B1 (pl) * | 1992-12-17 | 1999-06-30 | Pfizer | Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
CZ288955B6 (cs) | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi |
DE59500788D1 (de) * | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
JPH089637A (ja) * | 1994-06-20 | 1996-01-12 | Shindengen Electric Mfg Co Ltd | Fetによる出力スイッチの駆動回路 |
WO1996031510A1 (en) | 1995-04-03 | 1996-10-10 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
US5804685A (en) * | 1995-06-07 | 1998-09-08 | Neurogen Corporation | Deazapurine derivatives: a new class of CRF1 specific ligands |
US5644057A (en) * | 1995-05-12 | 1997-07-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
JPH08329674A (ja) * | 1995-06-02 | 1996-12-13 | Hitachi Ltd | 半導体装置 |
ES2203642T3 (es) | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
ES2172670T3 (es) | 1995-07-06 | 2002-10-01 | Novartis Ag | Pirrolpirimidinas y procedimientos para su preparacion. |
JP2001507340A (ja) * | 1996-11-26 | 2001-06-05 | アメリカン・サイアナミド・カンパニー | 抗癌薬としてのビアリール−ピリドキナゾリノン誘導体 |
-
1997
- 1997-11-05 US US09/308,602 patent/US6413971B1/en not_active Expired - Fee Related
- 1997-11-05 CA CA002272705A patent/CA2272705C/en not_active Expired - Fee Related
- 1997-11-05 CN CN97199662A patent/CN1237177A/zh active Pending
- 1997-11-05 KR KR1019990704587A patent/KR20000057228A/ko not_active Application Discontinuation
- 1997-11-05 BR BR9713552-6A patent/BR9713552A/pt unknown
- 1997-11-05 IL IL12982597A patent/IL129825A0/xx unknown
- 1997-11-05 JP JP10524465A patent/JP2000505109A/ja active Pending
- 1997-11-05 WO PCT/IB1997/001393 patent/WO1998023613A1/en not_active Application Discontinuation
- 1997-11-05 EP EP97909525A patent/EP0946554A1/en not_active Ceased
- 1997-11-05 AU AU47189/97A patent/AU4718997A/en not_active Abandoned
- 1997-11-07 HN HN1997000146A patent/HN1997000146A/es unknown
- 1997-11-20 PE PE1997001057A patent/PE17299A1/es not_active Application Discontinuation
- 1997-11-20 AP APAP/P/1997/001146A patent/AP9701146A0/en unknown
- 1997-11-25 AR ARP970105506A patent/AR010740A1/es unknown
- 1997-11-25 CO CO97068959A patent/CO4650037A1/es unknown
- 1997-11-26 PA PA19978442001A patent/PA8442001A1/es unknown
- 1997-11-26 MA MA24878A patent/MA26452A1/fr unknown
- 1997-11-26 ID IDP973768A patent/ID18958A/id unknown
- 1997-11-26 TN TNTNSN97192A patent/TNSN97192A1/fr unknown
- 1997-11-26 HR HR60/041,846A patent/HRP970641A2/hr not_active Application Discontinuation
-
1999
- 1999-04-30 IS IS5041A patent/IS5041A/is unknown
- 1999-05-20 BG BG103417A patent/BG103417A/xx unknown
- 1999-05-24 OA OA9900107A patent/OA11051A/en unknown
- 1999-05-26 NO NO992524A patent/NO992524D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
HN1997000146A (es) | 1998-02-26 |
CA2272705C (en) | 2003-03-18 |
NO992524L (no) | 1999-05-26 |
NO992524D0 (no) | 1999-05-26 |
AU4718997A (en) | 1998-06-22 |
IS5041A (is) | 1999-04-30 |
CN1237177A (zh) | 1999-12-01 |
KR20000057228A (ko) | 2000-09-15 |
WO1998023613A1 (en) | 1998-06-04 |
JP2000505109A (ja) | 2000-04-25 |
ID18958A (id) | 1998-05-28 |
PE17299A1 (es) | 1999-02-19 |
AP9701146A0 (en) | 1998-01-31 |
HRP970641A2 (en) | 1998-10-31 |
US20020045630A1 (en) | 2002-04-18 |
IL129825A0 (en) | 2000-02-29 |
BG103417A (en) | 2000-06-30 |
US6413971B1 (en) | 2002-07-02 |
BR9713552A (pt) | 2000-01-25 |
PA8442001A1 (es) | 2000-05-24 |
CA2272705A1 (en) | 1998-06-04 |
CO4650037A1 (es) | 1998-09-03 |
OA11051A (en) | 2003-03-07 |
TNSN97192A1 (fr) | 2005-03-15 |
MA26452A1 (fr) | 2004-12-20 |
EP0946554A1 (en) | 1999-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR010740A1 (es) | Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestos | |
PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
CL2008002768A1 (es) | Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades. | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
ES2139959T3 (es) | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. | |
AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
UY28691A1 (es) | Derivados de difenilazetidona | |
AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
AR039601A1 (es) | Derivados de nitrosodifenilamina y composiciones farmaceuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologias que se caracterizan por estres oxidativo | |
AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR009145A1 (es) | Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden | |
CO2022000700A2 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
UY38304A (es) | Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen | |
BR112022005558A2 (pt) | Compostos farmacêuticos | |
AR041720A1 (es) | Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen | |
UY28656A1 (es) | Derivados de indano heterocíclicos sustituidos y compuestos relacionados para el tratamiento de esquizofrenia |